Cure Alzheimer's Fund

Our Approach: We have a plan to end Alzheimer's, guided by leading scientists in the field. We're making tremendous progress. Join us.

Our Story: In 2004, we came together to fund Alzheimer's research in a whole new way. It's already paying off.

Our Commitment: We put every dollar to work. Our founders cover all administrative costs, which means every penny you donate will go directly to new research.

Research Updates

Public/Private Funding of Research on Alzheimer's Disease Guides Drug Discovery

New Research Co-Funded by Cure Alzheimer’s Fund Shows New Alzheimer’s Gene, CD33, May Hold Key to Treatment

High levels of exposure to air pollution may increase the risk of Alzheimer’s disease, according to a new study completed with a grant from the Cure Alzheimer’s Fund.

Traumatic Brain Injury (TBI) can lead to Neurodegenerative Syndromes that include Alzheimer Disease (AD) and Chronic Traumatic Encephalopathy (CTE)

Researchers Reprogramming Skin Cells into Brain Cells to Understand Alzheimer's Disease

Cure Alzheimer's Funded Research: New Findings Overturn Commonly Held Views of the NMDA Receptors Creating New Targets in the Treatment of Alzheimer's Disease

Cure Alzheimer’s Fund's Potential New Treatment to Stop Alzheimer's Disease: Molecular 'Tweezers' Break Up Toxic Aggregations of Proteins in Mouse Model

Eli Lilly Drug Slows Decline in Early-Stage Patients

Cure Alzheimer's-seeded Research Bears Fruit in Major New NIH-funded Study

News

Pfizer, Johnson & Johnson Announce Discontinuation of Bapineuzumab (IV form) Studies

August 7, 2012 • Alzheimer's in the News

After failed second clinical trial, Bapineuzumab studies are dropped for patients with mild to moderate Alzheimer’s disease, as the drug was ineffective...

Promising Study Suggests That a Drug for Immune Disorders May Offer Benefits to Alzheimer's Patients

July 25, 2012 • News

A new study of an existing drug for immune disorders that may have positive effects for Alzheimer’s patients has attracted national attention lately....

Alzheimer Drug, Bapineuzumab, Fails Its First Clinical Trial

July 24, 2012 • News

It was announced yesterday that Bapineuzumab, the Abeta immunotherapy drug, failed to meet cognitive and functional goals in a late stage trial of Alzheimer...

Massachusetts General Hospital number 1 in the current issue of U.S. News and World Report’s “Best Hospital” survey.

July 18, 2012 • News

Cure Alzheimer’s Fund is pleased to salute Massachusetts General Hospital for placing number 1 in the current issue of U.S. News and World Report’s...

Cure Alzheimer’s Fund Founding Board Member Phyllis Rappaport

June 12, 2012

Phyllis Rappaport, chair of the Phyllis & Jerome Lyle Rappaport Foundation and director of New Boston Fund Inc., is a co-founder and director of Cure...

Cure Alzheimer's Fund is a 501(c)(3) public charity. Cure Alzheimer’s Fund is a "doing business as" name for the Alzheimer's Disease Research Foundation, federal tax ID # 52-2396428.

Cure Alzheimer's Fund meets all 20 BBB Charity Standards

GuideStar